Alastair Hutchison1, Andrew Whelton2, Ravi Thadhani3, Heinrich Achenbach4, Andrea Vergani5, Jingyang Wu6, Gillian Hall7. 1. Renal Dialysis Unit, Manchester Royal Infirmary and Manchester Academic Health Science Centre, Manchester, United Kingdomalastair.hutchison@dchft.nhs.uk. 2. School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. 3. Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA. 4. Clinical Research and Development, Shire, Zug, Switzerland. 5. Clinical Research and Development, Shire, Lexington, Massachusetts, USA. 6. Biostatistics, Shire, Lexington, Massachusetts, USA. 7. Gillian Hall Epidemiology Ltd., London, United Kingdom.
Abstract
BACKGROUND/AIMS: This post-marketing observational study assessed the long-term safety of lanthanum carbonate (LaC) in US patients with end-stage renal disease (NCT00567723). METHODS: Patients (≥18 years old) undergoing dialysis, who had Medicare as their primary healthcare payer, and records in the United States Renal Data System were followed-up for 5 years. Patients who had received LaC for at least 12 consecutive weeks formed the exposed cohort. During the same time period, patients who had undergone dialysis for at least 12 consecutive weeks and had been treated with any other phosphate binder formed the primary comparator cohort. A historical cohort was also evaluated. Primary outcomes were all-cause mortality, and time to and incidence of first bone-fracture event requiring hospitalization. Secondary outcomes were time to first occurrence of and incidence of specific gastrointestinal (GI) disease, liver disease, malignancy, and major infectious episode requiring hospitalization. - Results: 2,026 and 8,094 patients were included in the exposed and primary comparator cohorts, respectively. A Cox proportional hazards model showed that patients receiving LaC were not at increased risk of all-cause mortality (adjusted hazard ratio 0.94; 95% CI 0.88-1.01; p = 0.078), bone fractures (0.86; 0.71-1.05; p = 0.130), specific GI disease (0.86; 0.76-0.97; p = 0.015), liver disease (0.88; 0.70-1.09; p = 0.236), malignancy (0.85; 0.54-1.34; p = 0.496), or major infectious episodes (0.87; 0.80-0.94; p < 0.001) requiring hospitalization compared with primary comparator patients. CONCLUSIONS: LaC was not associated with increased risk of mortality, bone fractures, or any secondary outcome.
BACKGROUND/AIMS: This post-marketing observational study assessed the long-term safety of lanthanum carbonate (LaC) in US patients with end-stage renal disease (NCT00567723). METHODS: Patients (≥18 years old) undergoing dialysis, who had Medicare as their primary healthcare payer, and records in the United States Renal Data System were followed-up for 5 years. Patients who had received LaC for at least 12 consecutive weeks formed the exposed cohort. During the same time period, patients who had undergone dialysis for at least 12 consecutive weeks and had been treated with any other phosphate binder formed the primary comparator cohort. A historical cohort was also evaluated. Primary outcomes were all-cause mortality, and time to and incidence of first bone-fracture event requiring hospitalization. Secondary outcomes were time to first occurrence of and incidence of specific gastrointestinal (GI) disease, liver disease, malignancy, and major infectious episode requiring hospitalization. - Results: 2,026 and 8,094 patients were included in the exposed and primary comparator cohorts, respectively. A Cox proportional hazards model showed that patients receiving LaC were not at increased risk of all-cause mortality (adjusted hazard ratio 0.94; 95% CI 0.88-1.01; p = 0.078), bone fractures (0.86; 0.71-1.05; p = 0.130), specific GI disease (0.86; 0.76-0.97; p = 0.015), liver disease (0.88; 0.70-1.09; p = 0.236), malignancy (0.85; 0.54-1.34; p = 0.496), or major infectious episodes (0.87; 0.80-0.94; p < 0.001) requiring hospitalization compared with primary comparator patients. CONCLUSIONS: LaC was not associated with increased risk of mortality, bone fractures, or any secondary outcome.
Authors: Brenda Motheral; John Brooks; Mary Ann Clark; William H Crown; Peter Davey; Dave Hutchins; Bradley C Martin; Paul Stang Journal: Value Health Date: 2003 Mar-Apr Impact factor: 5.725
Authors: Patrick C D'Haese; Goce B Spasovski; Aleksander Sikole; Alastair Hutchison; Tony J Freemont; Sylvie Sulkova; Charles Swanepoel; Svetlana Pejanovic; Llubica Djukanovic; Alessandro Balducci; Giorgio Coen; Waldysaw Sulowicz; Anibal Ferreira; Armando Torres; Slobodan Curic; Milan Popovic; Nada Dimkovic; Marc E De Broe Journal: Kidney Int Suppl Date: 2003-06 Impact factor: 10.545
Authors: Naya Huang; Huiyan Li; Li Fan; Qian Zhou; Dongying Fu; Lin Guo; Chunyan Yi; Xueqing Yu; Haiping Mao Journal: Front Med (Lausanne) Date: 2021-12-01